Cantor Fitzgerald analyst Jennifer Kim lowered the firm’s price target on Checkpoint Therapeutics to $14 from $19 and keeps an Overweight rating on the shares, citing the assumed future exercise of outstanding warrants related to the company’s recent offerings. Cantor believes that the potential peak sales opportunity for Checkpoint’s lead pipeline asset, cosibelimab, remains underappreciated, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CKPT:
- Checkpoint Therapeutics reports Q2 EPS ($1.05), consensus (78c)
- Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- MidCoast Council deploys Check Point Infinity
- Checkpoint to sell 3.2M shares at $3.09 in registered direct offering
- Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market